Search Results

Featured Stories

Toggle

Showing 10 of 877 results

Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the...

Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bact

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg...

Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Associatio

Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...

Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Trea

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first...

Teva Reports First Quarter 2021 Financial Results

Revenues of $4.0 billion GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.63 Cash flow used in operating activities of $405 million Free cash flow of $59 million Full year 2021 business outlook...

Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clini

Four posters examine the long-term efficacy, safety, and tolerability of AUSTEDO in patients with tardive dyskinesia and a review of clinical outcome measures in schizophrenia TEL AVIV, Israel &...

Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with A

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 ...

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reductio

Findings describe long-term and real-world data across post-hoc and retrospective analyses TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of...